Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Targeting the androgen receptor.

Friedlander TW, Ryan CJ.

Urol Clin North Am. 2012 Nov;39(4):453-64. doi: 10.1016/j.ucl.2012.07.003. Review.

PMID:
23084523
2.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
3.

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).

Gupta E, Guthrie T, Tan W.

BMC Urol. 2014 Jul 25;14:55. doi: 10.1186/1471-2490-14-55. Review.

4.

Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.

Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8. Review.

5.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
6.

Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.

Kim W, Ryan CJ.

Curr Treat Options Oncol. 2012 Jun;13(2):189-200. doi: 10.1007/s11864-012-0188-2. Review.

PMID:
22539224
7.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

8.

[New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].

Brasso K, Thomsen FB, Berg KD, Røder MA, Iversen P.

Ugeskr Laeger. 2013 Sep 30;175(40):2328-32. Review. Danish.

PMID:
24079321
9.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

10.

Persistent androgen receptor addiction in castration-resistant prostate cancer.

Schweizer MT, Yu EY.

J Hematol Oncol. 2015 Nov 13;8:128. doi: 10.1186/s13045-015-0225-2. Review.

11.

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.

Semenas J, Dizeyi N, Persson JL.

Drug Des Devel Ther. 2013 Aug 27;7:875-81. doi: 10.2147/DDDT.S45703. eCollection 2013. Review.

12.

Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.

Bambury RM, Rathkopf DE.

Urol Oncol. 2016 Aug;34(8):348-55. doi: 10.1016/j.urolonc.2015.05.025. Epub 2015 Jul 7. Review.

PMID:
26162486
13.

Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.

Zhu H, Garcia JA.

Curr Oncol Rep. 2013 Apr;15(2):105-12. doi: 10.1007/s11912-013-0300-1. Review.

PMID:
23371447
14.

Targeting the androgen receptor pathway in prostate cancer.

Chen Y, Sawyers CL, Scher HI.

Curr Opin Pharmacol. 2008 Aug;8(4):440-8. doi: 10.1016/j.coph.2008.07.005. Epub 2008 Aug 12. Review.

15.

Targeting the androgen receptor in prostate cancer.

Culig Z.

Expert Opin Pharmacother. 2014 Jul;15(10):1427-37. doi: 10.1517/14656566.2014.915313. Epub 2014 Jun 2. Review.

PMID:
24890318
16.

Landmarks in hormonal therapy for prostate cancer.

Hammerer P, Madersbacher S.

BJU Int. 2012 Oct;110 Suppl 1:23-9. doi: 10.1111/j.1464-410X.2012.11431.x. Review.

17.

[Pathophysiology and therapy of castration-resistant prostate cancer].

Merseburger AS, Kuczyk MA, Wolff JM.

Urologe A. 2013 Feb;52(2):219-25. doi: 10.1007/s00120-012-3054-8. Review. German.

PMID:
23160609
18.

Novel concepts in androgen receptor blockade.

Hsieh AC, Ryan CJ.

Cancer J. 2008 Jan-Feb;14(1):11-4. doi: 10.1097/PPO.0b013e318161d13e. Review.

PMID:
18303477
19.

Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.

De Maeseneer DJ, Van Praet C, Lumen N, Rottey S.

Urol Oncol. 2015 Jul;33(7):310-21. doi: 10.1016/j.urolonc.2015.01.008. Epub 2015 Feb 21. Review.

PMID:
25708954
20.

Targeting CYP17: established and novel approaches in prostate cancer.

Yap TA, Carden CP, Attard G, de Bono JS.

Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28. Review.

PMID:
18619560

Supplemental Content

Support Center